Anja K Büscher1, Nora Celebi2, Peter F Hoyer3, Hanns-Georg Klein4, Stefanie Weber5, Julia Hoefele6. 1. Pediatric Nephrology, Pediatrics II, University Children's Hospital Essen, Essen, Hufelandstrasse 55, 45122, Essen, Germany. anja.buescher@uk-essen.de. 2. Department of Medicine IV, University Hospital Tübingen, Tübingen, Germany. 3. Pediatric Nephrology, Pediatrics II, University Children's Hospital Essen, Essen, Hufelandstrasse 55, 45122, Essen, Germany. 4. Center for Human Genetics and Laboratory Diagnostics Dr. Klein, Dr. Rost and Colleagues, Martinsried, Germany. 5. University Children's Hospital, Marburg, Germany. 6. Institute of Human Genetics, Technical University of Munich, Munich, Germany.
Abstract
BACKGROUND: In 2010, INF2 mutations were associated with autosomal-dominant focal segmental glomerulosclerosis (FSGS), clinically presenting with moderate proteinuria in adolescence. However, in the meantime, cases with more severe clinical courses have been described, including progression to end-stage renal disease (ESRD) during childhood. INF2 mutations in patients with isolated FSGS are clustered in exons 2 to 4, encoding the diaphanous inhibitory domain, involved in the regulation of the podocyte actin cytoskeleton. METHODS: We report a family with 14 affected individuals (autosomal-dominant mode of inheritance), most of whom presented with nephrotic-range proteinuria, hypertension, and progressive renal failure. Four members received a kidney transplant without disease recurrence. Two patients underwent renal biopsy with the result of minimal-change glomerulopathy and IgA nephropathy respectively. We performed mutational analysis of ACTN4, CD2AP, COQ6, INF2, LAMB2, NPHS1, NPHS2, PLCE1, TRPC6, and WT1 in the index patient by next-generation sequencing. Additionally, in 6 affected and 2 unaffected family members target diagnostics were performed. RESULTS: We identified a novel heterozygous mutation c.490G>C (p.(Ala164Pro) in exon 3 of the INF2 gene in the index patient and 6 additionally examined affected family members. In silico analysis predicted it as "probably damaging". Additionally, three patients and 2 unaffected relatives harbored a novel heterozygous variant in ACTN4 (c.1149C>G, p.(Ile383Met)) with uncertain pathogenicity. CONCLUSION: Mutations in INF2 are associated with familial proteinuric diseases - irrespective of the presence of FSGS and in the case of rapid disease progression. Therefore, mutational analysis should be considered in patients with renal histology other than FSGS and severe renal phenotype.
BACKGROUND: In 2010, INF2 mutations were associated with autosomal-dominant focal segmental glomerulosclerosis (FSGS), clinically presenting with moderate proteinuria in adolescence. However, in the meantime, cases with more severe clinical courses have been described, including progression to end-stage renal disease (ESRD) during childhood. INF2 mutations in patients with isolated FSGS are clustered in exons 2 to 4, encoding the diaphanous inhibitory domain, involved in the regulation of the podocyte actin cytoskeleton. METHODS: We report a family with 14 affected individuals (autosomal-dominant mode of inheritance), most of whom presented with nephrotic-range proteinuria, hypertension, and progressive renal failure. Four members received a kidney transplant without disease recurrence. Two patients underwent renal biopsy with the result of minimal-change glomerulopathy and IgA nephropathy respectively. We performed mutational analysis of ACTN4, CD2AP, COQ6, INF2, LAMB2, NPHS1, NPHS2, PLCE1, TRPC6, and WT1 in the index patient by next-generation sequencing. Additionally, in 6 affected and 2 unaffected family members target diagnostics were performed. RESULTS: We identified a novel heterozygous mutation c.490G>C (p.(Ala164Pro) in exon 3 of the INF2 gene in the index patient and 6 additionally examined affected family members. In silico analysis predicted it as "probably damaging". Additionally, three patients and 2 unaffected relatives harbored a novel heterozygous variant in ACTN4 (c.1149C>G, p.(Ile383Met)) with uncertain pathogenicity. CONCLUSION: Mutations in INF2 are associated with familial proteinuric diseases - irrespective of the presence of FSGS and in the case of rapid disease progression. Therefore, mutational analysis should be considered in patients with renal histology other than FSGS and severe renal phenotype.
Entities:
Keywords:
End-stage renal disease; FSGS; INF2; IgA nephropathy; Proteinuria
Authors: J M Kaplan; S H Kim; K N North; H Rennke; L A Correia; H Q Tong; B J Mathis; J C Rodríguez-Pérez; P G Allen; A H Beggs; M R Pollak Journal: Nat Genet Date: 2000-03 Impact factor: 38.330
Authors: I M Rood; E M H F Bongers; D Lugtenberg; I H H T Klein; E J Steenbergen; J F M Wetzels; J K J Deegens Journal: Neth J Med Date: 2016-02 Impact factor: 1.422
Authors: Malte P Bartram; Sandra Habbig; Caroline Pahmeyer; Martin Höhne; Lutz T Weber; Holger Thiele; Janine Altmüller; Nina Kottoor; Andrea Wenzel; Marcus Krueger; Bernhard Schermer; Thomas Benzing; Markus M Rinschen; Bodo B Beck Journal: Hum Mol Genet Date: 2016-01-05 Impact factor: 6.150
Authors: Claudine H Kos; Tu Cam Le; Sumita Sinha; Joel M Henderson; Sung Han Kim; Hikaru Sugimoto; Raghu Kalluri; Robert E Gerszten; Martin R Pollak Journal: J Clin Invest Date: 2003-06 Impact factor: 14.808
Authors: Anja K Büscher; Bodo B Beck; Anette Melk; Julia Hoefele; Birgitta Kranz; Daniel Bamborschke; Sabrina Baig; Bärbel Lange-Sperandio; Theresa Jungraithmayr; Lutz T Weber; Markus J Kemper; Burkhard Tönshoff; Peter F Hoyer; Martin Konrad; Stefanie Weber Journal: Clin J Am Soc Nephrol Date: 2015-12-14 Impact factor: 8.237
Authors: Elizabeth J Brown; Johannes S Schlöndorff; Daniel J Becker; Hiroyasu Tsukaguchi; Stephen J Tonna; Andrea L Uscinski; Henry N Higgs; Joel M Henderson; Martin R Pollak Journal: Nat Genet Date: 2009-12-20 Impact factor: 38.330
Authors: Samet Bayraktar; Julian Nehrig; Ekaterina Menis; Kevser Karli; Annette Janning; Thaddäus Struk; Jan Halbritter; Ulf Michgehl; Michael P Krahn; Christian E Schuberth; Hermann Pavenstädt; Roland Wedlich-Söldner Journal: J Am Soc Nephrol Date: 2020-06 Impact factor: 10.121
Authors: Hua Sun; Chandra Perez-Gill; Johannes S Schlöndorff; Balajikarthick Subramanian; Martin R Pollak Journal: J Am Soc Nephrol Date: 2020-12-22 Impact factor: 10.121